Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.42 |
| ▸ | KDR | P35968 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6846646 | 0.78 | PLAU (0.47) | FGFR1KDRRAB9ACSF1R | |
| SCHEMBL6848240 | 0.78 | TP53 (0.57) | MAPTFGFR1KDRTP53CSF1R | |
| SCHEMBL6848447 | 0.78 | FGFR1 (0.49) | MAPTFGFR1KDRTP53CSF1R | |
| Trifluoroacetic Acid SCHEMBL6841401 | 0.77 | FGFR1 (0.44) | FGFR1KDRCSF1R | |
| SCHEMBL6846474 | 0.74 | FGFR1 (0.41) | MAPTPOLBFGFR1KDRRAB9A | |
| Trifluoroacetic Acid SCHEMBL6846473 | 0.74 | FGFR1 (0.44) | FGFR1KDRCSF1R | |
| SCHEMBL6846500 | 0.71 | MRGPRX4 (0.46) | — | |
| Hydrochloric Acid SCHEMBL6841286 | 0.71 | MRGPRX4 (0.45) | — | |
| SCHEMBL846841 | 0.70 | TRPV1 (0.56) | MAPTKDRRAB9AALDH1A1 | |
| SCHEMBL1051317 | 0.70 | RAB9A (0.60) | MAPTPOLBRAB9ATP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092747-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BENDER STEVEN LEE (US) | 2004-05-13 | — | — | US | disclosed |
| US-6635641-B2 | For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis | AGOURON PHARMACEUTICALS, INC. | 2003-10-21 | — | — | US | disclosed |
| EP-1252146-A1 | AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2001053274-A1 | AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092747-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BRAF, CNKSR1, UACA | MAPT 899/4885POLB 2588/4885FGFR1 147/4885 |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BRAF, CNKSR1, UACA | MAPT 899/4885POLB 2588/4885FGFR1 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.